Skip to content
On March 8, 2023, during the first markup of health care bills this year, the Health Subcommittee of the House Energy and Commerce Committee […]
Legislation potentially banning QALYs due to discrimination is under review Read More »
The 11th International IP Index was published by the U.S. Chamber of Commerce, highlighting the danger of COVID-19 IP infringement and its potential impact
U.S. Chamber’s IP Index highlights progress and new threats Read More »
To assure the broad adoption of cutting-edge preventative measures that can shield Americans in the future, vaccine policy has to be changed, according to
Why vaccine policy must keep up with the science Read More »
Health and Human Services (HHS) is set to assess three drug payment models for Medicare and Medicaid in response to President Biden’s proposal to
HHS releases new drug payment models—here’s what you need to know Read More »
On Thursday, the Centers for Medicare & Medicaid Services (CMS) released its proposed timeline for penalizing drug makers whose prices rise faster than inflation.
CMS releases timeline for inflation rebate on drug price increases Read More »
The Biotechnology Innovation Organization (BIO) recently told the U.S. Patent and Trademark Office (USPTO) that proposed changes to the pharmaceutical patent process are flawed—and
BIO says that proposed changes to pharma patents would harm innovation Read More »
Partisan divisions were on display at a joint hearing of the House Energy & Commerce Committee’s Health and Oversight & Investigations subcommittees, as Republicans
Administration officials return to Congress to discuss COVID-19 response Read More »
In his State of the Union speech last night, President Joe Biden hailed the end of the COVID-19 emergency while ignoring the contribution of
State of the Union: Biden’s remarks on drug price controls and biomedical innovation Read More »
The Inflation Reduction Act’s drug price controls have been a hot topic during the BIO CEO and Investor Conference—and one that has hampered an
We’re already seeing the impact of drug price controls, say biotech CEOs Read More »
With the 118th Congress picking up steam, the Biotechnology Innovation Organization’s (BIO) Federal Government Relations team shared what to expect in health care and
What BIO’s watching on health care and agriculture policy in 2023 Read More »
